Funding Boosts Development of NanoGalaxy Platform and Lead Candidate BRZ-101 for Type 1 Diabetes
Why is targeted gene delivery a critical challenge in the biotech industry? BreezeBio, a biotechnology company headquartered in South San Francisco, is addressing this issue with its proprietary NanoGalaxy platform. The company, formerly known as GenEdit, has secured $60 million in Series B financing to advance its first internal therapeutic programs toward clinical trials and expand the NanoGalaxy platform. This funding will enable BreezeBio to develop genetic medicines with curative potential, starting with BRZ-101, a novel immune modulation therapy for type 1 diabetes.
“BreezeBio is solving one of the most significant challenges in gene therapy, targeted delivery, and in doing so is helping define the next generation of genetic medicines,” said Vincent Jeong, Managing Director at Yuanta Investment, lead investor in the Series B financing. This investment marks a pivotal moment for BreezeBio, positioning it to address significant unmet needs in autoimmune and other serious diseases.
Key Insights at a Glance
- Targeted Delivery: BreezeBio’s NanoGalaxy platform enables precise delivery of genetic payloads to specific cell types.
- Clinical Progress: BRZ-101, the lead therapeutic candidate, is advancing into IND-enabling studies.
- Strategic Partnerships: BreezeBio continues its collaboration with Genentech, a member of the Roche Group.
- Investor Confidence: The Series B financing is led by new investors, including Yuanta Investment and DSC Investment.
Why Targeted Delivery is a Critical Challenge in Gene Therapy
Targeted delivery of genetic payloads is a significant hurdle in gene therapy, often leading to off-target effects and reduced efficacy. BreezeBio’s NanoGalaxy platform addresses this by using nanoparticles to deliver genetic materials, such as mRNA, to specific cell types with precision. This technology has demonstrated targeted delivery to the immune, cardiac, pulmonary, and central nervous systems, making it a game-changer in the development of genetic medicines. The ability to deliver genetic payloads to the right cells without affecting the broader immune system is crucial for treating autoimmune diseases like type 1 diabetes, where the immune system mistakenly attacks the body’s own cells.
The Regulatory Clock Is Already Running for Gene Therapy Developers
Just as a clock ticks down to a critical deadline, BreezeBio is racing against time to bring its innovative therapies to market. The company’s lead candidate, BRZ-101, is designed to restore immune tolerance in type 1 diabetes by delivering autoantigens and tolerogenic co-factors to antigen-presenting cells. This process induces antigen-specific regulatory T cells (Tregs) that block the autoimmune response without compromising the overall immune function. Preclinical testing has shown promising results, with BRZ-101 inducing antigen-specific immune tolerance in multiple models of autoimmune disease, including the NOD mouse model of diabetes. The company is now advancing BRZ-101 into IND-enabling studies, a crucial step toward clinical trials.
BreezeBio Advances NanoGalaxy Platform with Strategic Partnerships
BreezeBio is leveraging its NanoGalaxy platform to develop a robust pipeline of genetic medicines. The platform’s nanoparticles are engineered to deliver genetic payloads to specific cell types, including immune cells and tissues in the heart, lung, and central nervous system. In addition to its internal programs, BreezeBio continues its multi-year collaboration and licensing agreement with Genentech, a member of the Roche Group. This partnership has already achieved initial milestones, and R&D activities are progressing. The Series B financing will further support the expansion of the NanoGalaxy platform, including the development of ligands conjugated to nanoparticles for additional tissue and cell specificity, such as delivery to T cells for in vivo CAR-T therapeutic development.
Future Outlook
The future of genetic medicine is rapidly evolving, and BreezeBio is at the forefront of this transformation. With the NanoGalaxy platform and a robust pipeline, the company is well-positioned to address significant unmet needs in autoimmune and other serious diseases. The next milestone for BreezeBio is advancing BRZ-101 into clinical trials, a critical step that could redefine the treatment landscape for type 1 diabetes.
Conclusion
BreezeBio’s Series B financing and the advancement of its NanoGalaxy platform represent a significant leap forward in gene therapy. For the biotech industry, this development underscores the importance of targeted delivery in creating effective genetic medicines. How is your organization preparing to leverage these advancements in your research and development efforts? Join the conversation in the comments below.
About BreezeBio
BreezeBio is a biotechnology company developing genetic medicines enabled by precise, non-viral delivery across biologically relevant tissues. Using its proprietary NanoGalaxy® platform, BreezeBio engineers nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types, with demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. The company is advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology, led by BRZ-101 to restore immune tolerance in type 1 diabetes. BreezeBio is headquartered in California in the South San Francisco area.
Source link: https://www.businesswire.com/
